Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.

Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies

Abstract

Background cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials.Methods in the main study, ONTARGET, a double-blind, double-dummy, randomised controlled trial, the effects on cardiovascular outcomes of standard doses of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), an angiotensin-receptor blocker (telmisartan), and a combination of the drugs were evaluated in 25 620 participants. In the parallel TRANSCEND trial, the effects of telmisartan were compared with those of placebo in 5926 participants intolerant to ACE inhibitors. Secondary outcomes included cognitive impairment (defined by investigator-reported diagnosis of dementia or significant cognitive dysfunction, or a score of ≤ 23 on the Mini-Mental State Examination [MMSE]) and cognitive decline (a decrease of ≤ 3 points on the MMSE from baseline during follow-up). Analyses were by intention to treat. We pooled data from these studies to identify baseline predictors of cognitive impairment and its frequency according to mean systolic blood pressure during follow-up. These studies were registered with ClinicalTrials.gov, number NCT00153101.Findings During a median duration of 56 months (IQR 51-64) of follow-up in ONTARGET, cognitive impairment occurred in 652 (8%) of 7865 patients allocated ramipril, 584 (7%) of 7797 allocated telmisartan, and 618 (8%) of 7807 allocated combination treatment (combination vs ramipril, odds ratio [OR] 0·95, 95% CI 0·85-1·07, p= 0·39; telmisartan vs ramipril, OR 0·90, 0·80-1·01, p = 0·06). Corresponding figures for cognitive decline were 1314 (17%), 1279 (17%), and 1240 (17%) in each of the groups, respectively (telmisartan vs ramipril, OR 0·97, 0·89-1·06, p= 0·53; combination vs ramipril, OR 0·95, 0·88-1·04, p=0·28). In TRANSCEND, cognitive impairment occurred in 239 (9%) of 2694 participants allocated telmisartan compared with 245 (9%) of 2689 allocated placebo (OR 0·97, 0·81-1·17, p= 0·76). The corresponding figures for cognitive decline were 454 (17%) and 412 (16%; OR 1·10, 0·95-1·27, p= 0·22).Interpretation In patients with cardiovascular disease or diabetes, different approaches to blocking of the renin-angiotensin system had no clear effects on cognitive outcomes. Although patients with the lowest systolic blood pressure had the greatest preservation of cognitive function, meta-regression analyses did not show any benefits of blood-pressure lowering on cognition over several years of treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70250-7

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 216

Metadata

Authors
Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., Paolasso, E., Holwerda, N., Chazova, I., Binbrek, A., Young, J., & Yusuf, S.
Affiliations
  • The University of Sydney (AU)
  • Population Health Research Institute (CA)
  • University of the Philippines Manila (PH)
  • Charité – Universitätsmedizin Berlin (DE)
  • University of Cape Town (ZA)
  • Boehringer Ingelheim (Germany) (DE)
  • Estudios Clínicos Latinoamérica (AR)
  • Elisabeth-TweeSteden Ziekenhuis (NL)
  • Rashid Hospital (AE)
  • Cleveland Clinic (US)
Corresponding author
Anderson, Craig
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2011-01
Volume
10
Issue
1
Pages
43-53
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2098900970
Cited by
216
References
41
Citations by year
2026: 9 · 2025: 7 · 2024: 15 · 2023: 13 · 2022: 7 · 2021: 16 · 2020: 15 · 2019: 9 · 2018: 17 · 2017: 17 · 2016: 18 · 2015: 13 · 2014: 10 · 2013: 16 · 2012: 19
FWCI
10.76
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
renin-angiotensin system blockade, cognitive impairment, cognitive decline, dementia, ramipril, telmisartan, atherosclerotic cardiovascular disease, ONTARGET trial, TRANSCEND trial, systolic blood pressure, ACE inhibitors, angiotensin receptor blockers, older adults, cardiovascular risk factors, Mini-Mental State Examination
MeSH terms
Telmisartan, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Benzimidazoles, Benzoates, Cardiovascular Diseases, Cognition Disorders, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Mental Status Schedule, Neuropsychological Tests, Renin-Angiotensin System, Odds Ratio, Treatment Outcome, Ramipril, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. https://app.cochat.ai/papers/10.1016/s1474-4422(10)70250-7
The paper
Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., Paolasso, E., Holwerda, N., Chazova, I., Binbrek, A., Young, J., & Yusuf, S. (2011). Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(10)70250-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.